drugset
drugset / Trial / NCT01276769

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

NCT01276769 ↗

Phase 2 Unknown 80 enrolled Chinese Academy of Medical Sciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and sensitive to carboplatin.

Timeline

Start
2008-01
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Comparator Epirubicin Small molecule 75 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications

triple-negative breast carcinoma